Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — J.P. Morgan Healthcare Conference 2024
23 slides from Tarsus Pharmaceuticals's conference presentation, Jan 8, 2024
Slide 1: Leading the Way in Category Creation
Leading the Way in Category Creation J A N U A R Y 2 0 2 4 Sulma, an XDEMVY® Patient
Slide 2: Forward-looking statements
2 This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations about future events that we believe may affect our financial
Slide 3: Expert Leadership Team With Decades of Eye Care, Product Launch and Market Building Experience
3 Expert Leadership Team With Decades of Eye Care, Product Launch and Market Building Experience Bobby Azamian, M.D., Ph.D. CEO & Chairman Former CEO/CMO Metavention with extensive investment/entrepreneurial experience with Versant & Third Rock Ventures Aziz Mottiwala Chief Commercial Officer Jeff F
Slide 4: A Category-Creating Approach to Delivering Blockbuster Medicines and Serving Millions of Patients
4 The first and only FDA-approved therapy for Demodex blepharitis A category-creating medicine with a clear value proposition Compelling patient outcomes driving: • Rapid uptake • Ongoing waves of eye care provider (ECP) adoption • Strong traction with payers and high-value net price “Pipeline in a
Slide 5: Beginning With a Large, Durable Eye Care Market
5 Beginning With a Large, Durable Eye Care Market $21$15 by 2028 Source: EvaluatePharma ophthalmic revenues Posterior E X P E C T E D OPHTHALMIC MARKET Anterior Category creation has led to eye care blockbusters • Dry Eye Disease, Thyroid Eye Disease, Anti-VEGF in Wet AMD*, Prostaglandins in Glaucom
Slide 6: Demodex Blepharitis: A Pervasive and Damaging Eyelid Disease
6 • Caused by an infestation of Demodex mites • Patients can suffer eyelid inflammation, redness, irritation and a negative impact on daily activities • Quickly diagnosed during a routine eye exam through the identification of collarettes • Potential for serious clinical implications if left untreat
Slide 7: Easily Diagnosed Through the Presence of Collarettes
7 Easily Diagnosed Through the Presence of Collarettes have Demodex blepharitis1 of patients with collarettes WATCH VIDEO 1. Gao YY, Di Pascuale MA, Li W, et al. Invest Ophthalmol Vis Sci. 2005;46(9):3089-3094. For Investor Purposes Only
Slide 8: Demodex Blepharitis is a Potential $1B+ Opportunity
8 Demodex Blepharitis is a Potential $1B+ Opportunity G O A L 1. Wilson J Ophthalmology 2015, 435606, 2014; 2. Symphony claims data; 3. Titan collarette prevalence study; 4.Market Scope 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025; 5. White et al., Clin Ophthalmology 2019:
Slide 9: XDEMVY: An eye care product unlike any other
►An innovative, category-creating therapeutic ►A strong value proposition for patients, ECPs and payers ►A high-touch, market-building commercial plan ►Patent protection expected through 2038 The First and Only FDA-Approved Medicine for Demodex Blepharitis XDEMVY: An eye care p roduc t UNLIKE ANY OT
Slide 10: XDEMVY: Delivering for Patients
10 XDEMVY: Delivering for Patients B E F O R E A F T E R For Investor Purposes Only B E F O R E A F T E R B E F O R E A F T E R Patient outcomes and experiences may vary.
Slide 11: XDEMVY: A High-Value, Market-Building Launch
11 XDEMVY: A High-Value, Market-Building Launch Setting a New Standard for Blockbuster-Potential Eye Care Launches • Action-oriented, visually focused physician and patient education campaigns • Peer-to-peer scientific exchange conducted by all-ECP medical field force • Deep eye care, biotech and pr
Slide 12: XDEMVY: Delivering on Expectations
12 XDEMVY: Delivering on Expectations To date • >50% repeat prescribers • Positive trend in new writers – moving from “interest” to “action” In the first month following product launch • Unique online/retail distribution model provides convenient access to >18K pharmacies • Patient out-of-pocket cos
Slide 13: Ongoing Waves of ECP Adoption
13 U T I L I Z AT I O N A C R O S S S E G M E N T S ONGOING PRESCRIBING AFTER 5-10 TRx† In less than 5 months XDEMVY Prescribers *As of Jan. 4, 2024 Early Adopters (Diagnosing and treating patients on Day 1) Eager Treaters (Ready for an FDA-approved solution; ramping TRx alongside patient successes)
Slide 14: A Clear Path to Blockbuster Potential
14 A Clear Path to Blockbuster Potential Strong Early Launch Trajectory ► Patients eager to share positive benefits of treatment ► Success stories created a positive prescribing feedback loop for ECPs ► Payers recognizing high-value benefit of XDEMVY Accelerated Impact ► Broad commercial coverage se
Slide 15: Pipeline
PIPELINE Abby, an XDEMVY Patient For Investor Purposes Only
Slide 16: A Category-Creating Pipeline With Near-Term Catalysts
16 Tarsus Product Portfolio Product Candidate Indication Formulation Preclinical Phase 1 Phase 2 Phase 3 Marketed Upcoming Catalyst XDEMVY Demodex blepharitis (US) Eye drop TP-03 Demodex blepharitis (EU) Eye drop Preservative-free formulation to be evaluated after FDA approval TP-03 Meibomian Gland
Slide 17: Meibomian Gland Disease: A Large, Underserved Eye Care Category
17 Meibomian Gland Disease: A Large, Underserved Eye Care Category No FDA-Approved Pharmacologic Treatment ~30-40M Americans impacted by MGD1,2 1. Milner, MS, et al. Curr Opin Ophthalmol 2017 Jan; 28 Suppl 1, 3–47; 2. Foulks GN, Bran AJ. Ocul Surf. 2003;1:107-12; 3. Titan collarette prevalence study
Slide 18: Ersa Phase 2a Trial for the Treatment of MGD with Demodex Mites
18 Ersa Phase 2a Trial for the Treatment of MGD with Demodex Mites 21.8 28.1 32.7 22.1 27.6 33.8 0 5 10 15 20 25 30 35 40 Baseline (N=21/18) Day 43 (N=20/18) Day 85 (N=20/18) Mean (± SE) MGSS Score Range 0-45 BID TID p<0.001 p<0.001 M ea n # of g la nd s 0.6 2.9 5.5 0.9 3 6.3 0 1 2 3 4 5 6 7 8 Basel
Slide 19: Rosacea – An Inflammatory Skin Condition
19 Rosacea – An Inflammatory Skin Condition Current Treatment Options Offer Limited Efficacy 1. Buddenkotte J. Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res.2018.7. 2. Source on file ~16M Americans impacted by rosacea1 ~3-5M Experience papulopustular rosacea (PPR)2 Ros
Slide 20: TP-04: Potential to be the First Topical to Address Root Cause of Disease
20 Topline data expected in 1Q 2024 Demodex Mites: Highly prevalent in the skin of patients with PPR and may contribute to the inflammatory response associated with the disease Patient Impact: Redness, swelling and/or pus-filled bumps TP-04: The lotilaner API has demonstrated potent ability across s
Slide 21: Lyme Disease – A Growing Public Health Crisis
21 Lyme Disease – A Growing Public Health Crisis No FDA-Approved Prophylaxis ~27M Americans at high-to- moderate infection risk $1.3B Impact to U.S. healthcare system Lyme Disease A tick-borne infection caused by the transmission of Borrelia burgdorferi For Investor Purposes Only
Slide 22: TP-05: Potential to Be the First and Only Durable, On-Demand Oral Prophylaxis for Lyme Disease
22 Topline data expected in 1Q 2024 Prevention is key: Strong patient/physician interest in an oral, on-demand, non-vaccine option that targets the tick – preventing exposure to the bacteria that causes Lyme Disease Patient Impact: Difficult to manage; long-term sequelae can progress to severe joint
Slide 23: A Category-Creating Approach to Delivering Blockbuster Medicines and Serving Millions of Patients
23 The first and only FDA-approved therapy for Demodex blepharitis A category-creating medicine with a clear value proposition Compelling patient outcomes driving: • Rapid uptake • Ongoing waves of eye care provider (ECP) adoption • Strong traction with payers and high-value net price “Pipeline in a
Tarsus Pharmaceuticals — J.P. Morgan Healthcare Conference 2024 on 6ix